Download Files:
Ilorasertib
$600 – $1,100
Products Details
Product Description
– Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1][2].
Web ID
– HY-16018
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H21FN6O2S
References
– [1]Yi-Chun Wang, et al. Abstract 858: Potent in vivo activity of the aurora kinase inhibitor ABT-348 in human acute myeloid leukemia and myelodysplastic syndrome xenograft models. Cancer Res (2012) 72 (8_Supplement): 858.|[2]Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
CAS Number
– 1227939-82-3
Molecular Weight
– 488.54
Compound Purity
– 98.0
SMILES
– O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 41.67 mg/mL (ultrasonic)
Target
– Aurora Kinase;PDGFR;VEGFR
Isoform
– Aurora A;Aurora B;Aurora C;PDGFRα;PDGFRβ;VEGFR1/Flt-1;VEGFR2/KDR/Flk-1;VEGFR3/Flt-4
Pathway
– Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
